The GBD study is arguably the most comprehensive global effort to quantify mortality, morbidity, and risk factors associated with a wide array of diseases, including cardiovascular disorders. By analyzing data collected over three decades, from 1990 to 2023, the study provides an unprecedented longitudinal perspective on how cardiovascular disease patterns have shifted across different regions, nations, and even subnational jurisdictions. This level of granularity is essential for tailoring effective interventions since cardiovascular disease remains the leading cause of death globally despite advances in medicine and technology.

A focal point of the event will be the presentation of updated data for 204 countries and territories, illuminating both emergent trends and persistent disparities in cardiovascular outcomes. These data sets incorporate a multitude of determinants including social, economic, and environmental factors, allowing experts to dissect how varying health system capacities influence disease burden. For example, the study explores the differential impact of ischemic heart disease, stroke, hypertensive heart disease, and other cardiovascular conditions in diverse demographic settings.

This detailed epidemiological mapping has profound significance for advancing United Nations Sustainable Development Goals (SDGs), particularly SDG 3.4, which targets a one-third reduction in premature mortality from non-communicable diseases (NCDs) by 2030. Cardiovascular diseases are a dominant subset within this domain, and the GBD findings empower policymakers, researchers, and clinicians with actionable intelligence to optimize prevention strategies, clinical management, and health system resource allocation on a global scale.

Understanding the dynamics of cardiovascular disease burden requires not only mortality statistics but also an evaluation of risk factor prevalence, healthcare accessibility, and socioeconomic determinants. The GBD 2023 report integrates metrics such as disability-adjusted life years (DALYs), years lived with disability (YLDs), and risk factor attribution to provide a multidimensional understanding of health loss. This technical rigor enables a sophisticated assessment of how factors like hypertension, tobacco use, unhealthy diet, and physical inactivity contribute to CVD prevalence and outcomes in different regions.

Moreover, the longitudinal data reveal critical insights into the effectiveness of existing healthcare interventions and identify gaps where health systems may be failing vulnerable populations. For instance, suboptimal control of hypertension and inequitable access to secondary prevention therapies remain obstacles in low- and middle-income countries. These findings underscore the necessity of bolstering primary care infrastructure and integrating cardiovascular health promotion into broader health agendas.

The collaboration between JACC and IHME leverages the complementary strengths of clinical cardiology expertise alongside advanced epidemiological modeling and big data analytics. These scholarly institutions are uniquely positioned to bridge research and practice, transforming vast quantities of health information into strategies that drive tangible improvements in cardiovascular outcomes. Their joint stewardship over this event reflects a commitment to disseminating knowledge through peer-reviewed publications and global forums.

For cardiovascular professionals, researchers, and health system leaders, this UNGA side event will serve as a nexus for discussion on translating data into practice. The exchange of evidence-based insights facilitates the development of precision public health approaches tailored to the diverse needs of populations affected by cardiovascular conditions. It also emphasizes the role of innovation in diagnostics, therapeutics, and digital health in addressing the evolving CVD landscape.

The meticulous data presented will also highlight subnational disparities within countries, providing a more nuanced appreciation of health inequities. Urban-rural divides, socioeconomic stratification, and access to quality care emerge as critical variables affecting cardiovascular health outcomes. This enhanced resolution in the GBD 2023 data is invaluable for local governments and health agencies aiming to implement targeted interventions that address specific community needs.

Speakers at the event will include leading epidemiologists, cardiologists, and public health experts who have contributed to the GBD study or are active in cardiometabolic research. Their discussions will contextualize the data within global health policy frameworks and emerging trends such as demographic aging, urbanization, and shifts in risk factor profiles. The exchange will foster collaborative opportunities to prioritize research, funding, and capacity-building initiatives to reduce the global cardiovascular disease burden.

This initiative aligns with the American College of Cardiology’s broader mission to advance cardiovascular care worldwide through education, advocacy, and clinical excellence. Over the past 75 years, the ACC has grown into an influential network of over 60,000 healthcare professionals, supported by its portfolio of peer-reviewed journals collectively known as JACC. These journals disseminate cutting-edge research across the spectrum of cardiovascular science, from basic mechanistic studies to pragmatic clinical trials and health services research.

The ACC’s commitment is demonstrated not only through scholarly publication but also through its global health programs and patient-centered initiatives. By supporting and co-hosting this UNGA side event, the ACC and IHME reinforce their leadership in uniting data science with clinical expertise to shape global cardiovascular health agendas. The resulting insights are anticipated to catalyze progress in prevention, treatment, and health system strengthening—key pillars for mitigating the staggering global toll of cardiovascular disease.

Ultimately, the GBD 2023 study outcomes presented at this forum will provide an empirical foundation for sustained global action against cardiovascular disease, highlighting both achievements and urgent challenges. As new epidemiological evidence emerges, the scientific community, policymakers, and clinicians must continue to adapt and innovate strategies to fulfill international commitments to reduce premature mortality and promote equitable heart health for all populations.

This event echoes a timely and essential moment, positioning cardiovascular disease eradication as not just a medical imperative but a socio-political priority rooted in robust data. By spotlighting comprehensive disease burden estimates and their policy relevance, the JACC and IHME collaboration advances a vital narrative: that data-driven solutions can and must fuel transformative improvements in global cardiovascular health.

Subject of Research: Global cardiovascular disease burden and epidemiological trends based on Global Burden of Disease 2023 study data

Article Title: The Global Burden of CVD: New Insights to Drive Progress

News Publication Date: September 24, 2025

Web References:

• https://www.acc.org/Tools-and-Practice-Support/Quality-Programs/Features/Forums-and-Summits/ACC-at-UNGA2025
• https://www.jacc.org/
• http://www.ACC.org

Keywords: Cardiovascular disease, Health care delivery, Health care costs, Health equity

Clonal hematopoiesis refers to the somatic mutations in hematopoietic stem cells that lead to the expansion of mutated clones within peripheral blood. This phenomenon, often silent, has been linked to a drastically increased probability of developing leukemia and other blood cancers. Moreover, evidence accumulated over recent years indicates a robust association between CH and adverse cardiovascular outcomes, including coronary artery disease, heart failure, and arrhythmias. The most frequently mutated driver genes implicated in CH, namely DNMT3A, TET2, and ASXL1, represent approximately 80% of cases and reflect the mutational landscape influenced by aging hematopoiesis.

Importantly, epidemiological studies have demonstrated that the prevalence of clonal hematopoiesis rises exponentially with age; over 10% of people aged 70 years and older harbor one or more of these mutations. Given this high prevalence and the significant health risks linked with CH, researchers have prioritized understanding factors that modulate clonal expansion. The current study focuses on addressing whether colchicine, a historically well-established anti-inflammatory drug primarily used to treat gout, could influence the growth dynamics of CH clones.

The LoDoCo2 trial, originally designed to test colchicine’s efficacy in reducing cardiovascular events in patients with chronic coronary disease, revealed a substantial 31% relative risk reduction in cardiovascular incidents with a daily 0.5 mg dose of colchicine. Building on these findings, the current subanalysis interrogated longitudinal blood samples from trial participants to assess the drug’s potential impact on the clonal architecture of hematopoietic mutations over time. Specifically, four sequential blood draws were performed: baseline, 30 days post-randomization, one year, and at the conclusion of the study.

Using next-generation sequencing technology, researchers quantified the burden and allelic fraction of key CH mutations across these time points. Additionally, inflammation biomarkers in the blood, which have been implicated in both clonal expansion and atherogenesis, were assayed during the initial three time points. The study’s advanced genomic and biomarker profiling provided a multidimensional perspective on how anti-inflammatory therapy intersects with genetic and cellular alterations in aging blood.

The results revealed that individuals receiving colchicine exhibited a markedly reduced rate of clonal expansion compared to placebo recipients. While placebo-treated participants showed a significant 14.9% increase annually in overall CH clone size, those on colchicine experienced a non-significant rise of merely 6.3% per year. Notably, this growth attenuation was especially pronounced for TET2-mutated clones. The TET2 clone size increased by only 9.1% annually among the colchicine group, contrasting sharply with a 29.6% increase in the placebo group, suggesting a specific vulnerability of TET2-mutated hematopoietic cells to anti-inflammatory mechanisms.

Michael Honigberg, MD, MPP, FACC, the study’s senior author and a cardiologist at Massachusetts General Hospital, emphasized the clinical relevance of these findings. Larger CH clones have consistently correlated with higher risks of cardiovascular disease and malignancy, with TET2 mutations linked particularly closely to increased cardiovascular risk. This study not only elucidates colchicine’s multifaceted benefits in reducing cardiovascular events but also raises the possibility that the drug may interrupt the pathogenetic expansion of deleterious clonal blood populations.

In a complementary investigation also published in JACC and unveiled at ESC Congress 2025, researchers examined the relationship between CH and cardiovascular disease risk specifically in an elderly female cohort. The Women’s Health Initiative Long Life Study enrolled over 6,600 women, with a median age of 80, to probe whether the impact of clonal hematopoiesis wanes in advanced age as some prior research suggested. Contradicting earlier assumptions, this study found that several CH subtypes, including TET2, ASXL1, and JAK2 mutations, were indeed associated with increased incident cardiovascular disease in these older women.

This finding confirms that clonal hematopoiesis remains a critical contributor to cardiovascular health and disease progression well into late adulthood. Such insights underscore the enduring need to consider CH when evaluating cardiovascular risk profiles among the elderly, a demographic population growing rapidly worldwide. The mechanistic links between inflammation, aging hematopoiesis, and vascular pathology are increasingly recognized as fertile ground for therapeutic intervention.

Editorial leadership from Harlan Krumholz, MD, FACC, Editor-in-Chief of JACC and Harold H. Hines Jr Professor of Medicine at Yale University, contextualized the broader implications of these studies. Clonal hematopoiesis serves as a pivotal intersection connecting aging biology, cardiovascular disease, and cancer pathophysiology. Advances in understanding how inflammation and somatic genetic alterations coalesce to shape disease trajectories open novel pathways for precision prevention and treatment strategies that target both genetic drivers and inflammatory mediators.

The cumulative evidence spotlights colchicine as a cost-effective, well-tolerated pharmacological tool with potential to modify underlying disease mechanisms beyond symptomatic relief or secondary prevention. Its ability to attenuate inflammatory signaling pathways, notably those involving the NLRP3 inflammasome and interleukin-1 β, combined with the demonstrated suppression of CH clone expansion, positions colchicine at the forefront of next-generation cardio-oncology paradigms.

As our population ages and the burden of cardiovascular disease and hematologic malignancies escalates, identifying interventions that mitigate foundational biological causes takes on paramount importance. The synergy of genomic medicine, longitudinal biomarker monitoring, and repurposed anti-inflammatory agents heralds a transformative era in individualized cardiovascular and cancer risk management.

Further research aimed at delineating the molecular crosstalk between mutated hematopoietic clones and the vascular microenvironment will be critical in optimizing treatment algorithms. Trials designed to verify colchicine’s effects on CH populations across diverse demographics, as well as exploring combination therapies targeting multiple pathogenic axes, are eagerly anticipated. The integration of these discoveries into clinical practice offers the promise of dramatically altering the course of age-associated chronic diseases.

In summary, the groundbreaking research presented at ESC Congress 2025 and published in JACC reveals colchicine’s unprecedented role in modulating clonal hematopoiesis, particularly mutations in TET2, which are intimately tied to cardiovascular disease and malignancy risk. These findings highlight innovative pathways to combat the intertwined epidemics of aging, inflammation, blood cancer, and heart disease, providing hope for novel preventative and therapeutic strategies that address the root causes of morbidity and mortality in elderly populations.

Subject of Research: Effects of low-dose colchicine on clonal hematopoiesis and cardiovascular disease risk in elderly populations

Article Title: Low-Dose Colchicine Attenuates Clonal Hematopoiesis Expansion and Reduces Cardiovascular Risk: Insights from the LoDoCo2 Trial Subanalysis

News Publication Date: Not explicitly stated, presented at ESC Congress 2025

Web References:

• American College of Cardiology
• Journal of the American College of Cardiology (JACC)

Keywords: Clonal hematopoiesis, colchicine, cardiovascular disease, TET2 mutation, DNMT3A, ASXL1, inflammation, aging, hematologic malignancies, LoDoCo2 trial, anti-inflammatory therapy, cardiovascular risk reduction